A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
One in seven drug supply chain issue reports tied to drug shortages
Apr 10, 2024
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
Nirmatrelvir-ritonavir does not speed up alleviation of COVID-19 symptoms
Apr 05, 2024
The time to sustained alleviation of COVID-19 symptoms was not significantly shorter with nirmatrelvir-ritonavir versus placebo.
Risk profile IDs COVID-19 patients who will benefit from baricitinib
Feb 26, 2024
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Biden looks to boost supply chain for vaccines and other medicines
By
Kathleen Steele Gaivin
Nov 29, 2023
President Biden on Monday said he plans to use the Defense Production Act to make more “essential medicines” in America in an effort to mitigate drug shortages and curb inflation.
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...
Paxlovid not helpful for reducing most post-COVID-19 conditions
Oct 31, 2023
No differences were seen in most post-COVID-19 conditions examined individually or by organ system, apart from a lower combined risk for venous thromboembolism and pulmonary embolism.
COVID-19 meds like Paxlovid will soon have big price tags
Oct 30, 2023
The pills still will be available at no cost until those bought earlier by the federal government run out.